Comparable stake leader
Pittman Scott M.
SEC ownership of Nuo Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001091596.
Disclosed value leader
Charles E. Sheedy
Comparable rows
4/8
Latest evidence
27 Aug 2026
- Public ticker
- AURX on OTC
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Pittman Scott M.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 8
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Pittman Scott M.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
27 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001091596
- Issuer location
- Houston, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Nuo Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Pittman Scott M.
Disclosed value leader
Charles E. Sheedy
Comparable rows
4/8
Latest evidence
27 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
4 rows are not safely comparable across share classes.
13D/G row: Pittman Scott M.
Quick read
Pittman Scott M. leads the comparable SEC ownership view at 12%.
4 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Pittman Scott M.'s linked filing trail.
Comparable ownership
Top 4
Pittman Scott M.
12%
Jacobs Paul Anthony
6.6%
Charles E. Sheedy
24%
Ancora Advisors LLC
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Pittman Scott M. |
13D/G
3/4/5
Director, 10%+ Owner
|
12%
|
$8,159,875
5,627,500 shares
|
+$25,302 | 29 May 2026 |
| Jacobs Paul Anthony |
13D/G
|
6.6%
|
$6,526,175
3,183,500 shares
|
$0 | 23 Jan 2026 |
| Charles E. Sheedy |
3/4/5
10%+ Owner
|
24%
|
$17,360,960
11,574,198 shares
|
— | 30 Jul 2025 |
| Ancora Advisors LLC |
13F
Company
|
0.01%
|
$4,277
4,700 shares
|
— | 30 Jun 2026 |
| David Emerson Jorden |
3/4/5
CEO/CFO, Director
|
—
mixed-class rows
|
$2,254,230
2,195,000 shares
mixed-class rows
|
-$290,461 | 27 Aug 2026 |
| Peter Clausen |
3/4/5
CSO/COO
|
—
mixed-class rows
|
$312,884
838,528 shares
mixed-class rows
|
— | 29 Jun 2026 |
| C. Eric Winzer |
3/4/5
Director
|
—
mixed-class rows
|
$250,922
203,050 shares
mixed-class rows
|
— | 29 Jun 2026 |
| Paul Mintz |
3/4/5
Director
|
—
mixed-class rows
|
$238,246
138,294 shares
mixed-class rows
|
— | 29 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$290,461.
Buys
$9,539
Insiders: 1
Sells
$300,000
Insiders: 1
Net
-$290,461
Shares: -191,227
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 8,773
Shares: 200,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 8,773 | 0 | $9,539 | $0 | +$9,539 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 200,000 | $0 | $300,000 | -$300,000 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-6 of 6 reporting-owner rows connected to Nuo Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
6
Largest Forms 3/4/5 holder
Charles E. Sheedy
Net 12M change
-$290,461
Latest report
27 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Charles E. Sheedy | 10%+ Owner | $17,360,960 | Mixed | 30 Jul 2025 | ||
| Pittman Scott M. | Director, 10%+ Owner | $7,830,574 | Mixed | 29 Jun 2026 | ||
| David Emerson Jorden | CEO/CFO, Director | $2,254,230 | -$290,461 | -11% | Filing P/S | 27 Aug 2026 |
| Peter Clausen | Cso/Coo | $312,884 | Mixed | 29 Jun 2026 | ||
| C. Eric Winzer | Director | $250,922 | Mixed | 29 Jun 2026 | ||
| Paul Mintz | Director | $238,246 | Mixed | 29 Jun 2026 |
Recent insider transactions for Nuo Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Emerson Jorden | AURX | Common Stock | Purchase | 0.39% | $8,695 | $1.09 | 7,984 | 2,070,000 | 28 Aug 2026 | Direct |
| David Emerson Jorden | AURX | Common Stock | Award | 0.39% | 7,984 | 2,070,000 | 28 Aug 2026 | Direct | ||
| David Emerson Jorden | AURX | Common Stock | Purchase | 0.04% | $844 | $1.07 | 789 | 2,062,016 | 27 Aug 2026 | Direct |
| David Emerson Jorden | AURX | Common Stock | Award | 0.04% | 789 | 2,062,016 | 27 Aug 2026 | Direct | ||
| David Emerson Jorden | AURX | Common Stock | Tax liability | -7.24% | -160,892 | 2,061,227 | 30 Jun 2026 | Direct | ||
| David Emerson Jorden | AURX | Common Stock | Options Exercise | 7.89% | 162,500 | 2,222,119 | 30 Jun 2026 | Direct | ||
| David Emerson Jorden | AURX | Option to purchase common stock | Options Exercise | -100% | -162,500 | 0 | 30 Jun 2026 | Direct | ||
| Scott M. Pittman | AURX | Common Stock | Tax liability | -0.73% | -39,604 | 5,400,396 | 30 Jun 2026 | Direct | ||
| Scott M. Pittman | AURX | Common Stock | Options Exercise | 0.74% | 40,000 | 5,440,000 | 30 Jun 2026 | Direct | ||
| Scott M. Pittman | AURX | Option to purchase common stock | Options Exercise | -100% | -40,000 | 0 | 30 Jun 2026 | Direct | ||
| C. Eric Winzer | AURX | Common Stock | Tax liability | -18.6% | -39,604 | 173,050 | 30 Jun 2026 | Direct | ||
| C. Eric Winzer | AURX | Common Stock | Options Exercise | 23.2% | 40,000 | 212,654 | 30 Jun 2026 | Direct | ||
| C. Eric Winzer | AURX | Option to purchase common stock | Options Exercise | -100% | -40,000 | 0 | 30 Jun 2026 | Direct | ||
| Peter Clausen | AURX | Option to purchase common stock | Award | 65,000 | 65,000 | 29 Jun 2026 | Direct | |||
| David Emerson Jorden | AURX | Option to purchase common stock | Award | 125,000 | 125,000 | 29 Jun 2026 | Direct | |||
| Scott M. Pittman | AURX | Option to purchase common stock | Award | 30,000 | 30,000 | 29 Jun 2026 | Direct | |||
| C. Eric Winzer | AURX | Option to purchase common stock | Award | 30,000 | 30,000 | 29 Jun 2026 | Direct | |||
| Paul Mintz | AURX | Option to Purchase Common Stock | Award | 30,000 | 30,000 | 29 Jun 2026 | Direct | |||
| David Emerson Jorden | AURX | Common Stock | Award | 0.64% | 13,245 | 2,085,000 | 05 Jun 2026 | Direct | ||
| Scott M. Pittman | AURX | Prepayment Restated Warrant (right to buy) | Award | 7,333 | 0 | 29 May 2026 | Direct | |||
| Scott M. Pittman | AURX | Second Restated Warrant (right to buy) | Award | 17,500 | 0 | 29 May 2026 | Direct | |||
| Scott M. Pittman | AURX | Prepayment Warrant (right to buy) | Disposed to Issuer | -100% | -7,516 | 0 | 29 May 2026 | Direct | ||
| Scott M. Pittman | AURX | Second Warrant (right to buy) | Disposed to Issuer | -100% | -36,750 | 0 | 29 May 2026 | Direct | ||
| Scott M. Pittman | AURX | Interim Warrant (right to buy) | Award | 17,450 | 17,450 | 29 May 2026 | Direct | |||
| Scott M. Pittman | AURX | Prepayment Warrant (right to buy) | Award | 7,516 | 0 | 23 Jan 2026 | Direct | |||
| Scott M. Pittman | AURX | Second Warrant (right to buy) | Award | 36,750 | 0 | 23 Jan 2026 | Direct | |||
| Scott M. Pittman | AURX | Initial Warrant (right to buy) | Award | 30,050 | 30,050 | 23 Jan 2026 | Direct | |||
| David Emerson Jorden | AURX | Common Stock | Tax liability | -1.23% | -25,381 | 2,046,374 | 01 Jan 2026 | Direct | ||
| David Emerson Jorden | AURX | Common Stock | Options Exercise | 6.42% | 125,000 | 2,071,755 | 01 Jan 2026 | Direct | ||
| C. Eric Winzer | AURX | Option to purchase common stock | Options Exercise | -100% | -68,750 | 0 | 31 Dec 2025 | Direct | ||
| C. Eric Winzer | AURX | Common Stock | Tax liability | -7.38% | -13,750 | 172,654 | 17 Dec 2025 | Direct | ||
| C. Eric Winzer | AURX | Common Stock | Options Exercise | 58.4% | 68,750 | 186,404 | 17 Dec 2025 | Direct | ||
| Paul Mintz | AURX | Common Stock | Tax liability | -7.74% | -9,091 | 108,294 | 09 Dec 2025 | Direct | ||
| Paul Mintz | AURX | Common Stock | Options Exercise | 74.2% | 50,000 | 117,385 | 09 Dec 2025 | Direct | ||
| David Emerson Jorden | AURX | Common Stock | Sale | -9.32% | $300,000 | $1.50 | -200,000 | 1,946,755 | 28 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.